Mammalian prions, transmissible agents causing lethal neurodegenerative diseases, are composed of assemblies of misfolded cellular prion protein (PrP) 1 . A novel PrP variant, G127V, was under positive evolutionary selection during the epidemic of kuru, an acquired prion disease epidemic of the Fore population in Papua New Guinea, and appeared to provide strong protection against disease in the heterozygous state 2 . We have now investigated the protective role of this variant and its interaction with the common worldwide M129V PrP polymorphism; V 127 was seen exclusively on a M 129 PRNP allele. Here we demonstrate that transgenic mice expressing both variant and wild type human PrP are completely resistant to both kuru and classical CJD prions (which are closely similar) but can be infected with variant CJD prions, a human prion strain resulting from exposure to BSE prions to which the Fore were not exposed. Remarkably however, mice expressing only PrP V 127 were completely resistant to all prion strains demonstrating a different molecular mechanism to M129V, which provides its relative protection against classical CJD and kuru in the heterozygous state. Indeed this single amino acid substitution (G→V) at a residue invariant in vertebrate evolution is as protective as deletion of the protein. Further study in transgenic mice expressing different ratios of variant and wild type PrP indicates that not only is PrP V 127 completely refractory to prion conversion, but acts as a potent dose-dependent inhibitor of wild type prion propagation.
Prions cause fatal neurodegenerative conditions such as scrapie in sheep, bovine spongiform encephalopathy (BSE) in cattle and Creutzfeldt-Jakob disease (CJD) in humans 1 . The fundamental molecular process, seeded propagation of assemblies of misfolded host protein, is increasingly recognised as being of importance in all the major human neurodegenerative diseases 3 . There is a common polymorphism, present worldwide, in the substrate protein in human prion disease, human prion protein (PrP), where either methionine (M) or valine (V) is present at residue 129. MV heterozygosity provides relative protection against acquired, sporadic, and some inherited prion diseases [4] [5] [6] and may have been selected during the evolution of modern humans by ancestral prion disease epidemics 7 . This protective effect is thought to relate to inhibition of homotypic protein-protein interactions 5, 8 although residue 129 also influences the propagation of particular prion strains via conformational selection 9, 10 . Heterozygosity at another polymorphism, E219K, also provides resistance to CJD in Japan 11 .
Kuru was a devastating epidemic prion disease transmitted by endocannibalism and restricted to a remote area in Papua New Guinea (PNG). We reported a novel PrP variant (G127V) amongst unaffected individuals which appeared be a resistance factor selected by the epidemic and unique to this region 2 . Given the proximity to residue 129, we considered that it may have a similar action to M129V, blocking homotypic interactions and exerting its protective effect only in the heterozygous state. No PRNP codon 127VV homozygotes were identified in the kuru-exposed population and V 127 was always seen on an M 129 allele 2 . We therefore generated multiple lines of transgenic mice, expressing only human PrP (HuPrP) on a congenic FVB/N Prnp o/o background, to investigate whether G127V was indeed protective and whether this protection was dependent on heterozygosity or was an intrinsic property of the variant protein. Additionally we investigated its interaction with the residue 129 polymorphism. Fig.  1 shows relative PrP C expression levels in all transgenic mice used in this study.
All transgenic lines were then challenged by intracerebral prion inoculation from wellcharacterised and previously transmitted human prion disease cases including all three PRNP codon 129 genotypes and comprising four cases of kuru, 12 cases of classical CJD and two cases of variant CJD (vCJD). Heterozygous HuPrP G 127 M 129 /V 127 M 129 mice (Tg35c × Tg183 and Tg35c × Tg190) (table 1), having the genotype associated with disease resistance in the kuru-exposed human population, proved completely resistant to all four kuru isolates (which included all three PRNP codon 129 genotypes and two molecular strain types) (Fig. 1a and (Tg152c) (table 2b) were fully susceptible with 100% attack rates. This is consistent with the population genetic data suggesting kuru resistance of G127V individuals. We have previously reported that prion strains seen in kuru brain are indistinguishable from those seen in classical CJD patients 19 . Similarly, none of four classical CJD isolates from patients of PRNP genotype 129MM transmitted to either line of G 127 M 129 /V 127 M 129 mice (table 2a and Fig. 1b) , while all four transmitted uniformly to Tg35c mice expressing wild type huPrP (Fig. 1b and table 2a) . Remarkably, however, occasional G 127 M 129 /V 127 M 129 mice developed clinical disease, and a larger number showed evidence of subclinical infection (positive PrP immunohistochemistry and/or western blot for PrP Sc ), on challenge with vCJD prions (table 2d and Extended Data Fig. 2 ). vCJD is a novel BSE-derived prion strain 17, 20, 21 to which the population in the kuruaffected area of PNG were not exposed.
The key question with respect to whether the protective effect of V 127 is via a similar mechanism to the M129V polymorphism was addressed by challenge of mice homozygous for HuPrP V 127 M 129 . While mice homozygous for wild type HuPrP G 127 M 129 or G 127 V 129 are both highly susceptible to CJD prions, remarkably mice homozygous for HuPrP V 127 M 129 were completely resistant to all 18 human prion disease isolates, including vCJD prions, with no clinical transmissions or evidence of subclinical infection ( Fig. 1a and Fig.1 and 4) . Interestingly, in these crosses some transmissions of kuru and classical CJD prions were seen (table 2b, Extended Data Fig. 4 and 5 ). In the Tg152c × Tg183 crosses, with a 3-fold excess of wild type PrP, subclinical infections were seen with four out of the 12 isolates used, and one kuru isolate (I10336) was associated with clinical disease (table 2b). However with the Tg152c × Tg190 crosses, with a 6-fold excess of wild type PrP, transmissions were seen from all isolates, the majority resulting in clinical disease (table 2b).
To further investigate the effect of HuPrP V 127 on prion propagation, we compared hemizygous Tg(HuPrP G 127 V 129 Prnp o/o )-152c mice with the Tg152c × Tg183 and Tg152c × Tg190 crosses (table 2c). The hemizygous line was challenged with two classical CJD and one kuru isolate that had resulted in a 100% attack rate in both crosses. Again, 100% attack rates were seen for all three isolates but the incubation periods were significantly shorter (P< 0.0001; table 2c) in the absence of HuPrP V 127 than in either cross. These data, together with comparison of the two crosses themselves (table 2b), are consistent with a dominant negative effect of HuPrP V 127 expression. Although dominant negative inhibition has been reported for other natural polymorphic residues of mammalian PrP in transgenic mice [22] [23] [24] none have shown complete prevention of prion conversion when expressed at a 1:1 ratio with wild type PrP. Dominant negative effects on yeast prion propagation have also been reported 25 .
Our transgenic modelling of the HuPrP G127V polymorphism demonstrates that it confers strong protection against prion disease in the heterozygous state. However, most importantly, the molecular basis of this effect is clearly distinct from that proposed for the well-established HuPrP M129V polymorphism which is protective against developing sporadic CJD only in the heterozygous state: inhibition of homotypic protein-protein interactions during the process of prion propagation. Here we demonstrate that HuPrP V 127 is intrinsically resistant to prion conversion and indeed capable of inhibiting propagation of wild type prions in a dose-dependent manner. Mice expressing only HuPrP V 127 appear as resistant to prion disease as PrP null mice 26 and understanding the structural basis of this effect may therefore provide critical insight into the molecular mechanism of mammalian prion propagation.
At its height when first recognised by Western medicine in 1957, kuru was a devastating epidemic largely affecting women and children and killing up to 2% of the population annually in some villages. Indeed some villages became largely devoid of young women of childbearing age. While collapse of the Fore population was prevented by cessation of endocannibalism in the late 1950s which interrupted the route of transmission and led to a gradual decline in incidence 27 , our data suggest that if transmission had continued the epicentre of the affected region might have been repopulated with kuru-resistant individuals as a population genetic response to the epidemic. Understanding the structural basis of why HuPrP V 127 is unable to propagate prions of multiple strain types may provide key insights into prion propagation and the development of rational therapeutics.
Methods Ethics Statement
Storage and biochemical analyses of post-mortem human brain samples and transmission studies to mice were performed with written informed consent from patients with capacity to give consent. Where patients were unable to give informed consent, assent was obtained from their relatives in accordance with UK legislation and Codes of Practice. Project Licence number 70/6454 which conformed to University College London institutional and ARRIVE guidelines (www.nc3rs.org.uk/ARRIVE/).
Generation of transgenic mice
The 759bp human PrP ORF was amplified by PCR with pfu polymerase from genomic DNA prepared from the brain of a patient with the 127V polymorphism on the 129M allele, using forward primer 5′-GTCGACCAGTCATTATGGCGAACCTT-3′ and reverse primer 5′-CTCGAGAAGACCTTCCTCATCCCACT-3′. Restriction sites Sal I and Xho I (underlined) were introduced in the forward and reverse primers respectively for cloning. The blunt ended PCR fragment generated by pfu polymerase was subcloned into Sma I digested pSP72 vector and sequenced to ensure that no spurious alterations had been introduced by the PCR and to confirm the presence of valine-127 and methionine-129 polymorphisms matching the patient DNA template. The amplified human PrP ORF with the confirmed polymorphisms was then isolated by Sal I and Xho I digestion. Subsequent subcloning into the Sal I site of the cosmid vector SHaCosTt, packaging and preparation of high quality DNA of the Not I transgene insert was as previously reported 12 . Microinjection of the purified Not I DNA fragment was carried out according to standard protocol into single cell eggs of Prnp null mice which had been backcrossed onto an FVB/N genetic background. Genotyping was performed by PCR and PrP expression levels estimated by western blot analysis as previously reported 12 
Transmission Studies
Strict bio-safety protocols were followed. Inocula were prepared, using disposable equipment for each inoculum, in a microbiological containment level 3 laboratory and inoculations performed within a class 1 microbiological safety cabinet as described previously 12, 19 . Ten mice per group of control G 127 M 129 Tg35c and G 127 V 129 Tg152c lines and 15 per group of newly generated V 127 M 129 Tg183, V 127 M 129 Tg190 lines and their respective crosses with Tg35c and Tg152c, were inoculated (see below) with human brain homogenates from neuropathologically confirmed patients comprising, four kuru cases, eight sporadic CJD cases, four iatrogenic CJD cases and two cases of vCJD. The genotype of each mouse was confirmed by PCR of ear punch DNA prior to inclusion and all mice were uniquely identified by sub-cutaneous transponders. Disposable cages were used and all cage lids and water bottles were also uniquely identified by transponder and remained with each cage of mice throughout the incubation period. Care of the mice was according to institutional guidelines. Mice (female, aged 6-8 weeks) were randomly assigned to experimental groups and anaesthetised with a mixture of halothane and O 2 , and intracerebrally inoculated into the right parietal lobe with 30 μl of a 1% (w/v) brain homogenate prepared in Dulbecco's phosphate buffered saline lacking Ca 2+ or Mg 2+ ions (D-PBS). All mice were thereafter examined daily for early indicators of clinical prion disease including piloerection, sustained erect ears, intermittent generalised tremor, unsustained hunched posture, rigid tail, mild loss of coordination,and clasping hind legs when lifted by the tail. Definite diagnosis of clinical prion disease (triggering experimental end point) was reached if mice exhibited any two early indicator signs in addition to one confirmatory sign, or any two confirmatory signs. The confirmatory signs included ataxia,impairment of righting reflex, dragging of hind limbs, sustained hunched posture, or significant abnormal breathing. Mice were killed (by CO 2 asphyxiation) if they exhibited any signs of distress or once a diagnosis of prion disease was established. At post-mortem brains from inoculated mice were removed, divided sagittally with half frozen and half fixed in 10% buffered formol saline. Subsequent immunohistochemical or biochemical investigations were performed blind to sample provenance.
Neuropathology and Immunohistochemistry
Fixed brain was immersed in 98% formic acid for 1 hour and paraffin wax embedded. Serial sections of 4 μm thickness were pre-treated by boiling for 10 min in a low ionic strength buffer (2.1 mM Tris, 1.3 mM EDTA, 1.1 mM sodium citrate, pH 7.8) before exposure to 98% formic acid for 5 min. Abnormal PrP accumulation was examined using anti-PrP monoclonal antibody ICSM 35 (D-Gen Ltd, London) on a Ventana automated immunohistochemical staining machine (Ventana Medical Systems Inc., Tucson, Arizona) using proprietary secondary detection reagents (Ventana Medical Systems Inc) before development with 3′3 diaminobenzedine tetrachloride as the chromogen 30 . Harris haematoxylin and eosin staining was done by conventional methods. Appropriate controls were used throughout.
Immunoblotting
Preparation of brain homogenates (10% (w/v) in D-PBS), proteinase K digestion (75 μg/ml for 1 h at 37°C) and subsequent immunoblotting was performed as described previously 28, 30 . Blots were probed with anti-PrP monoclonal antibody ICSM 35 (D-Gen Ltd, London) in conjunction with an anti-mouse IgG-alkaline phosphatase conjugate and development in chemiluminescent substrate (CDP-Star; Tropix Inc). Primary screening of brain homogenates was performed blind to sample identity. 28 † Attack rate is defined as the total number of both clinically affected and sub-clinically infected mice as a proportion of the total number of inoculated mice. Sub-clinical prion infection was assessed by immunoblotting and/or immunohistochemical examination of brain. Incubation periods are reported for clinically affected mice in days; where n ≥ 3 the mean ± SEM is reported with the number of mice contributing to the mean shown in parentheses, otherwise individual incubation times are given. In groups where no clinical transmission of prion disease was observed, the attack rate represents subclinical infection only and the interval between inoculation and death (from either senescence, culling due to inter-current illness or termination of the experiment) is reported as >x-y days. ‡ Mean incubation periods for all 3 isolates are significantly lower in Tg152c hemizygotes than in Tg190 × Tg152c heterozygotes (P<0.0001; twotailed unpaired t-test).
Nature. Author manuscript; available in PMC 2015 December 25. (days p.i), days post inoculation; vCJD, variant CJD; sCJD, sporadic CJD; iCJD, iatrogenic CJD; GH, growth hormone; DM, dura mater * According to classification of Hill et al. 28 † Attack rate is defined as the total of clinically affected and sub-clinically infected mice as a proportion of the number of inoculated mice. Subclinical prion infection was assessed by immunoblotting and/or immunohistochemical examination of brain. As no clinical transmission of prion disease was observed the interval between inoculation and death (from either senescence, culling due to inter-current illness or termination of the experiment) is reported as >x-y days.
